NYSEARCA:XLV - NYSE Arca - US81369Y2090 - ETF - Currency: USD
The company said its medical-surgical segment struggled with ongoing stapling market pressures and temporary shifts in U.S. distributor buying patterns.
CEO Stéphane Bancel said the company remains focused on driving sales and achieving up to 10 product approvals by 2027, as well as removing nearly $1 billion in costs by the end of this year.